


RECEIVED

AUG 01 2001 #3

TECH CENTER 1600/2900

Page 1 of 3



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1735.0440001/RWE/BECAPPLICATION NO.
09/769,420APPLICANTS
Cai et al.FILING DATE
January 26, 2001GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
Jm	AA1	3,406,168	10/15/1968	Schmidt	260	239.3	12/06/1966
Jm	AB1	4,261,730	04/14/1981	Bollinger et al.	71	94	08/09/1978
Jm	AC1	6,028,111	02/22/2000	Pero et al.	514	620	02/27/1997
	AD1						
	AE1						
	AF1						
	AG1						
	AH1						
	AI1						
	AJ1						
	AK1						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
Jm	AP1	0 807 633 A2	11/19/1997	Europe			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Jm	AR	2	Atwell, G.J. et al., "Potential Antitumor Agents. VII. Bisquaternary Salts," J. Med. Chem. 11:300-305, American Chemical Society (1968)
Jm	AS	2	Balcells, M. et al., "Synthesis of Phenoxyphenyl Pyridine and Pyrazine Carboxamides. Activity against <i>Cydia pomonella</i> (L.) Eggs," J. Agric. Food Chem. 48:83-87, American Chemical Society (2000).
Jm	AT	2	Cooper, G.H. and Rickard, R.L., "Reductive Acylation of 5-Nitropyridines with Anhydrides of Acetic, Phthalic, and Succinic Acids," J. Chem. Soc. C 19:3257-3260, Chemical Society (1971)

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

AUG 01 2001



TECH CENTER 1600/2900

	FORM PTO-1449		ATTY. DOCKET NO. 1735.0440001/RWE/BEC	APPLICATION NO. 09/769,420
	INFORMATION DISCLOSURE STATEMENT			
	APPLICANTS Cai et al.		FILING DATE January 26, 2001	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA2						
	AB2						
	AC2						
	AD2						
	AE2						
	AF2						
	AG2						
	AH2						
	AI2						
	AJ2						
	AK2						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
gm	AL2	1 573 576	08/28/1980	Great Britain			Yes No
	AM2	2000-256358	09/19/2000	Japan			Yes √No
	AN2	WO 99/24404	05/20/1999	WIPO			Yes No
	AO2	WO 00/06550	02/10/2000	WIPO			Yes √No
	AP2	WO 00/55114	09/21/2000	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
gm	AR	10	Doležal, M. et al., "Synthesis and Antimycobacterial, Antifungal, and Photosynthesis-Inhibiting Evaluation of Some Anilides of Substituted Pyrazine-2-carboxylic Acids," <i>Chem. Papers</i> 54:245-248, Slovak Academy of Sciences (2000).
gm	AS	10	Doležal, M. et al., "Synthesis and Photosynthesis-Inhibiting Activity of Some Anilides of Substituted Pyrazine-2-carboxylic Acids," <i>Chem. Papers</i> 53:126-130, Veda (1999).
gm	AT	10	Liégeois, J.-F. F. et al., "New Pyridobenzodiazepine Derivatives as Potential Antipsychotics: Synthesis and Neurochemical Study," <i>J. Med. Chem.</i> 36:2107-2114, American Chemical Society (1993)

EXAMINER	DATE CONSIDERED
	
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>	

RECEIVED

AUG 01 2001

TECH CENTER 1600/2900
Page 3 of 3

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1735.0440001/RWE/BECAPPLICATION NO.
09/769,420APPLICANTS
Cai et al.FILING DATE
January 26, 2001GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA3						
	AB3						
	AC3						
	AD3						
	AE3						
	AF3						
	AG3						
	AH3						
	AI3						
	AJ3						
	AK3						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
fy	AL3	WO 00/62778	10/26/2000	WIPO	—	—	Yes No
fr	AM3	WO 01/02354	01/11/2001	WIPO	—	—	Yes √No
fr	AN3	WO 01/21598	03/29/2001	WIPO	—	—	Yes No
	AO3						Yes No
	AP3						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

fy	AR	11	Palanki, M.S.S. et al., "Inhibitors of NF-κB and AP-1 Gene Expression: SAR Studies on the Pyrimidine Portion of 2-Chloro-4-trifluoromethylpyrimidine-5-[N-(3',5'-bis(trifluoromethyl)-phenyl)carboximide], " <i>J. Med. Chem.</i> 43:3995-4004, American Chemical Society (2000)
fr	AS	11	White, G.A., "Substituted 2-Methylbenzanilides and Structurally Related Carboxamides: Inhibition of Complex II Activity in Mitochondria from a Wild-Type Strain and a Carboxin-Resistant Mutant Strain of <i>Ustilago maydis</i> , " <i>Pest. Biochem. Physiol.</i> 34:255-276, Academic Press, Inc. (1989)
TC	AT	11	International Search Report for International Patent Application No. PCT/US01/02478, mailed May 31, 2001


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

#2
RECEIVED

TECH CENTER 1600 2900
JUL 02 2001



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT


ATTY. DOCKET NO. 1735.0440001/RWE/BEC
APPLICATION NO. 09/769,420
APPLICANT CAI et al.
FILING DATE January 26, 2001
GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
93	AL1	WO 95/25723	09/28/1995	WIPO			Yes No
81	AM1	WO 96/20721	07/11/1996	WIPO			Yes No
72	AN1	WO 99/36391	07/22/1999	WIPO			Yes No
92	AO1	WO 00/44216	08/03/2000	WIPO			Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
92	AR	1	Batteux, F. et al., "Gene Therapy of Experimental Autoimmune Thyroiditis by In Vivo Administration of Plasmid DNA Coding for Fas Ligand," <i>J. Immunol.</i> 162:603-608, The American Association of Immunologists (January 1999).
47	AS	1	Boirivant, M. et al., "Lamina Propria T Cells in Crohn's Disease and Other Gastrointestinal Inflammation Show Defective CD2 Pathway-Induced Apoptosis," <i>Gastroenterol.</i> 116:557-565, American Gastroenterological Association (March 1999).
8	AT	1	Coven, T.R. et al., "PUVA-induced lymphocyte apoptosis: Mechanism of action in psoriasis," <i>Photodermatol. Phytoimmunol. Photomed.</i> 15:22-27, Munksgaard (February 1999).

EXAMINER		DATE CONSIDERED	7/10/02
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1735.0440001/RWE/BECAPPLICATION NO.
09/769,420APPLICANT
CAI *et al.*FILING DATE
January 26, 2001GROUP
1614

TECH CENTER 1600/2900

Page 2 of 8
JUN 02 2001

RECEIVED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

gn	AR	2	Ellis, R.E. <i>et al.</i> , "Mechanisms and Functions of Cell Death," <i>Annu. Rev. Cell. Biol.</i> 7:663-698, Annual Reviews, Inc. (1991).
gn	AS	2	Friesen, C. <i>et al.</i> , "Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells," <i>Nature Med.</i> 2:574-577, Nature Publishing Group (1996).
gn	AT	2	Greenwald, R.B. <i>et al.</i> , "Drug Delivery Systems Employing 1,4- or 1,6-Elimination: Poly(ethylene glycol) Prodrugs of Amine-Containing Compounds," <i>J. Med. Chem.</i> 42:3657-3667, American Chemical Society (September 1999). (Published on Web, August 13, 1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



TECH CENTER 1600/2900

Page 3 of 8

RECEIVED
JUN 02 2001

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1735.0440001/RWE/BECAPPLICATION
09/769,420APPLICANT
CAI *et al.*FILING DATE
January 26, 2001GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Hy	AR	<u>3</u>	Heenen, M. <i>et al.</i> , "Methotrexate induces apoptotic cell death in human keratinocytes," <i>Arch. Dermatol. Res.</i> 290:240-245, Springer-Verlag (1998).
rz	AS	<u>3</u>	Infante, A.J. <i>et al.</i> , "The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis," <i>J. Pediatr.</i> 133:629-633, Mosby (1998).
Tu	AT	<u>3</u>	Leu, Y.-L. <i>et al.</i> , "Design and Synthesis of Water-Soluble Glucuronide Derivatives of Camptothecin for Cancer Prodrug Monotherapy and Antibody-Directed Enzyme Prodrug Therapy (ADEPT)," <i>J. Med. Chem.</i> 42:3623-3628, American Chemical Society (September 1999). (Published on Web, August 24, 1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1735.0440001/RWE/BECAPPLICATION NO.
09/769,420APPLICANT
CAI et al.FILING DATE
January 26, 2001GROUP
1614

TECH CENTER 1600/2900

Page 4 of 8

JUN 02 2001

RECEIVED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>4</u>	López-Hoyos, M. et al., "Regulation of B cell apoptosis by Bcl-2 and Bcl-X _L and its role in the development of autoimmune diseases (Review)," <i>Int. J. Mol. Med.</i> 1:475-483, D.A. Spandidos (1998).
	AS	<u>4</u>	Los, M. et al., "Cross-Resistance of CD95- and Drug-Induced Apoptosis as a Consequence of Deficient Activation of Caspases (ICE/Ced-3 Proteases)," <i>Blood</i> 90:3118-3129, The American Society of Hematology (1997).
	AT	<u>4</u>	O'Reilly, L.A. and A. Strasser, "Apoptosis and autoimmune disease," <i>Inflamm. Res.</i> 48:5-21, Birkhäuser Verlag (January 1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1735.0440001/RWE/BECAPPLICATION NO.
09/769,420APPLICANT
CAI et al.FILING DATE
January 26, 2001GROUP
1614

TECH CENTER 1600/2900

Page 5 of 5
JUL 02 2001

RECEIVED




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>5</u>	Ohsako, S. and K.B. Elkon, "Apoptosis in the effector phase of autoimmune diabetes, multiple sclerosis and thyroiditis," <i>Cell Death Differ.</i> 6:13-21, Stockton Press (January 1999).
	AS	<u>5</u>	Orrenius, S., "Apoptosis: molecular mechanisms and implications for human disease," <i>J. Internal Med.</i> 237:529-536, Blackwell Science Ltd. (1995).
	AT	<u>5</u>	Ozawa, M. et al., "312-nanometer Ultraviolet B Light (Narrow-Band UVB) Induces Apoptosis of T Cells within Psoriatic Lesions," <i>J. Exp. Med.</i> 189:711-718, The Rockefeller University Press (February 1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1735.0440001/RWE/BECAPPLICATION NO
09/769,420APPLICANT
CAI *et al.*FILING DATE
January 26, 2001GROUP
1614

TECH CENTER 1600/2900

Page 02 of 2001

RECEIVED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

gn	AR	6	Savill, J., "Apoptosis in resolution of inflammation," <i>J. Leukocyte Biol.</i> 61:375-380, Society for Leukocyte Biology (1997).
TR	AS	6	Schmitt, E. <i>et al.</i> , "The Bcl-xL and Bax- α control points: modulation of apoptosis induced by cancer chemotherapy and relation to TPCK-sensitive protease and caspase activation," <i>Biochem. Cell Biol.</i> 75:301-314, NRC Canada (1997).
gn	AT	6	Thornberry, N.A., "The caspase family of cysteine proteases," <i>Br. Med. Bull.</i> 53:478-490, The British Council (1997).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1735.0440001/RWE/BECAPPLICATION NO.
09/769,420APPLICANT
CAI et al.FILING DATE
January 26, 2001GROUP
1614

TECH CENTER 1600/2900

JUN 02 2001

RECEIVED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

TH	AR	7	Thornberry, N.A., "Caspases: key mediators of apoptosis," <i>Chemistry & Biology</i> 5:R97-R103, Current Biology Ltd. (1998).
TH	AS	7	Vaishnaw, A.K. et al., "The molecular basis from apoptotic defects in patients with CD95 (Fas/Apo-1) mutations," <i>J. Clin. Invest.</i> 103:355-363, American Society for Clinical Investigation (February 1999).
TH	AT	7	Wakisaka, S. et al., "Modulation by proinflammatory cytokines of Fas/Fas ligand-mediated apoptotic cell death of synovial cells in patients with rheumatoid arthritis (RA)," <i>Clin. Exp. Immunol.</i> 114:119-128, Blackwell Science (1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1735.0440001/RWE/BECAPPLICATION NO.
09/769,420APPLICANT
CAI et al.FILING DATE
January 26, 2001GROUP
1614

TECH CENTER 1600/2900

JUL 02 2001

RECEIVED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

84	AR	8	Wyllie, A.H., "Cell death: a new classification separating apoptosis from necrosis," in <i>Cell death in biology and pathology</i> , Bowen, I.D. and R.A. Lockshin, eds., Chapman and Hall, 1981, pp. 9-34.
84	AS	8	Wyllie, A.H. et al., "Cell Death: The Significance of Apoptosis," <i>Intl. Rev. Cytol.</i> 68:251-306, Academic Press, Inc. (1980).
84	AT	8	Zhou, T. et al., "Bisindolymaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases," <i>Nature Med.</i> 5:42-48, Nature Publishing Group (January 1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.